Trial Profile
A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab, mycophenolate, ciclosporin and corticosteroids) in renal transplantation
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Ciclosporin; Corticosteroids; Daclizumab; Mycophenolate mofetil
- Indications Renal transplant rejection
- Focus Adverse reactions
- Acronyms Bone Protection study
- 28 Feb 2019 Status changed from recruiting to discontinued.
- 12 Aug 2011 New trial record